Abstract
With the first readouts of trials of antibodies against COVID-19 appearing and others coming thick and fast, Nature Biotechnology asked a group of experts to comment on the challenges and timelines for these products.
MeSH terms
-
Antibodies / immunology
-
Antibodies / therapeutic use*
-
Betacoronavirus / immunology
-
Betacoronavirus / pathogenicity
-
COVID-19
-
Coronavirus Infections / immunology
-
Coronavirus Infections / therapy*
-
Coronavirus Infections / virology
-
Humans
-
Pandemics*
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / therapy*
-
Pneumonia, Viral / virology
-
SARS-CoV-2